• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    MEN1611, a PI3K inhibitor, combined with trastuzumab (T) +/- fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01)

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    AnnOncPiccart.pdf
    Size:
    138.5Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Piccart, M.
    Borrego, M. R.
    Arkenau, H. T.
    Escriva-De-Romani, S. I.
    Howell, Sacha J
    Hennequin, A.
    Jimenez-Rodriguez, B.
    Del Conte, G.
    Simonelli, M.
    Palleschi, M.
    Duhoux, F.
    Uribe, B.
    Curigliano, G.
    Waters, S.
    Aftimos, P. G.
    Wildiers, H.
    Tosi, D.
    Amair-Pinedo, F.
    Pellacani, A. U. E.
    Laurent, D. O.
    Show allShow less
    Affiliation
    Medical Oncology Clinic, Institute Jules Bordet, Brussels, Belgium
    Issue Date
    2021
    
    Metadata
    Show full item record
    Abstract
    Background MEN1611 (MEN) is an oral PI3K inhibitor active on the p110? mut and WT, ? and ? isoforms, while sparing the ?. B-PRECISE-01 is an ongoing phase 1b study investigating MEN in combination with T � F. No dose-limiting toxicities (DLTs) were observed during the escalation step and MEN 48 mg BID was selected as Recommended Phase 2 Dose (R2PD) for cohort expansion (CE). Methods In this open-label, 2-arm study, eligible patients (pts) had HER2+/PIK3CAmut locally unresectable advanced or metastatic (a/m) BC and were treated with at least 2 prior anti-HER2 therapies in the metastatic setting including T. All pts received MEN+T, while F was added in hormone receptor positive (HR+) postmenopausal women. Pooled safety and efficacy data from the two subpopulations of CE are presented herein. Results As of March 2021, 42 female pts were treated: 36 of them with MEN 48 mg BID (18 MEN+T and 18 MEN+T+F). Median age 55 years (range 34-78), 25% premenopausal, ECOG PS 0-1: 95.2%. Median metastatic regimes 4; 57.1% had prior pertuzumab and 73.8% had prior T-DM1. Common treatment-emergent adverse events (TEAEs, ?20%) were diarrhea 64.3%, nausea 42.8%, asthenia 31%, decreased appetite 28.6%, anemia 28.6%, and hyperglycemia 23.8%. Most treatment-related AE (TRAEs) were reversible and manageable by supportive care. TRAEs caused treatment interruption in 14 pts (33.3%, 1 pt definitely) and dose reduction in 6 pts (16.7%, only allowed in CE) mostly hyperglycemia, diarrhea, nausea, asthenia and decreased appetite. Serious TRAEs were experienced by 8 pts (19%): hyperglycemia 3 pts, diarrhea 2 pts, general physical health deterioration, generalized edema, and pneumonitis (1 pt each). In the efficacy-evaluable population (n=29) 9 pts showed partial response (MEN+T 4/11, MEN+T+F 5/18), and 18 pts had stable disease (MEN+T 6/11, MEN+T+F 10/18) as best response. Seven pts were on treatment > 6 months (MEN+T 3, MEN+T+F 4), and 1 pt received MEN+T > 12 months. Conclusions MEN combined with T � F shows a manageable safety profile with encouraging duration of antitumoral activity in heavily pre-treated pts with HER2+/PIK3CAmut a/m BC. Recruitment for CE is open.
    Citation
    Piccart M, Ruiz Borrego M, Arkenau H-T, Escriv�-de-Roman� SI, Howell SJ, Hennequin A, et al. 266P MEN1611, a PI3K inhibitor, combined with trastuzumab (T) � fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced or metastatic (a/m) breast cancer (BC): Safety and efficacy results from the ongoing phase Ib study (B-PRECISE-01). Vol. 32, Annals of Oncology. Elsevier BV; 2021. p. S478�9.
    Journal
    Annals of Oncology
    URI
    http://hdl.handle.net/10541/624704
    DOI
    10.1016/j.annonc.2021.08.549
    Additional Links
    https://dx.doi.org/10.1016/j.annonc.2021.08.549
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.annonc.2021.08.549
    Scopus Count
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.